MyFinsight
Home
Blog
About
Income Statement
|
Cash Flow
|
Balance Sheet
|
Ratios
Cash Flow Overview
Unit: Dollar
Positive Cash Flow Breakdown
Proceeds from issuance of common...
Depreciation and amortization
Accounts payable and accrued exp...
Others
Negative Cash Flow Breakdown
Net loss
Prepaid expenses and other curre...
Change in fair value of derivati...
Others
Subscribe for Financial Insights
Page 1
Quarterly
123
Page 1
Cash Flow
2026-03-31
2025-12-31
2025-09-30
2025-06-30
Gain on marketable securities
-
0
0
0
Change in fair value of marketable securities
-
-
0
0
Accrued interest settled with common stock
-
0
0
0
Loss on settlement of convertible debt
-
0
0
0
Expense for debt issuance costs due to fair value election on convertible notes
-
0
-
-
Expense for issuance costs due to liability classified warrants
-
0
-
-
Loss on issuance of convertible notes - fair value option
-
0
-
-
Accrued interest income
-
0
0
0
Accounts payable and accrued expenses - related parties
-
0
0
0
Interest payments on convertible notes accounted for at fair value
0
-27,482
-27,480
-60,377
Accrued interest payable
-
0
0
0
Change in fair value of convertible notes
0
-60,433
-64,369
121,451
Other assets
-
0
-
-
Accrued interest payable - related parties
0
0
-590
-1,195
Net loss
-2,152,471
-2,614,895
-2,347,302
-6,759,472
Depreciation
-
-
1,008
29
Depreciation and amortization
633,340
290,107
-
-
Change in fair value of derivative liabilities
76,264
-91,149
2,427
14,316
Amortization of debt discount and finance fees
12,122
13,921
18,182
29,927
Gain on settlement of debt
-
-342,650
-
-
Stock-based compensation
35,018
214,750
134,318
583,899
Prepaid expenses
-
-205,339
-
83,472
Prepaid expenses and other current assets
323,604
-
880,497
-
Accounts payable and accrued expenses
335,951
-453,303
331,198
545,099
Change in operating lease asset and liabilities
-904
-904
-905
-650
Impairment of right-of-use asset
-
109,235
-
-
Net cash used in operating activities
-2,417,309
-973,012
-2,626,654
-5,881,979
Investment in marketable securities
-
0
0
0
Proceeds from disposition of marketable securities
-
0
0
0
Investment in developed technology related to molecule.ai asset acquisition
-
3,044,722
-
-
Payment for issuance costs related to liability-classified warrants
-
0
-
-
Payments made for capitalized software
36,000
12,000
-
-
Payment of convertible note payable
-
0
0
0
Net cash used in investing activity
-36,000
-3,056,722
0
0
Proceeds from exercise of pre-funded warrants
-
-
-
19,652
Repayment of note payable-related party
0
65,326
-
124,944
Proceeds from issuance of common stock and pre-funded warrants, net of placement agent costs of 322,051
0
1,329,673
0
4,080,000
Proceeds from note payable-related party
-
0
-
-
Proceeds from exercise of pre-funded warrants
-
349
19,802
-
Proceeds from issuance of common stock and pre-funded warrants, net of placement agent costs of 170,000
-
4,080,000
-
-
Repayment of note payable-related party
-
-
-190,270
-
Proceeds from convertible notes payable
-
0
-
-
Payment for finance costs
0
-4,262
0
78,414
Proceeds from issuance of pre-funded warrants, net of issuance costs of 235,514
-
2,264,485
-
-
Proceeds from issuance of common stock and pre-funded warrants, net of placement agent costs of 275,000
3,225,000
-5,409,673
0
5,409,673
Payment of other issuance costs for issuance of common stock and equity-classified warrants
15,750
0
31,199
526,460
Net cash provided by financing activities
3,209,250
2,269,096
-96,375
8,779,507
Net change in cash and cash equivalents
755,941
-1,760,638
-
-
Net change in cash and cash equivalents
755,941
-1,760,638
-2,723,029
2,897,528
Cash and cash equivalents, beginning of period
334,005
2,094,643
1,920,144
-
Cash and cash equivalents, end of period
1,089,946
334,005
2,094,643
-
Page 1
Unit: Dollar. Numbers labeled with * are estimated quarterly values.
Page 1
Buy us a coffee
Time Plot
Show the time plot by selecting a row from the table.
Cash Flow
Proceeds from issuance of
common stock and...
$3,225,000
Net cash provided by
financing activities
$3,209,250
Canceled cashflow
$15,750
Net change in cash
and cash...
$755,941
Canceled cashflow
$2,453,309
Payment of other
issuance costs for...
$15,750
Depreciation and
amortization
$633,340
Accounts payable and
accrued expenses
$335,951
Stock-based compensation
$35,018
Amortization of debt discount
and finance fees
$12,122
Net change in cash
and cash...
$755,941
Net cash used in
operating activities
-$2,417,309
Net cash used in
investing activity
-$36,000
Canceled cashflow
$1,016,431
Net loss
-$2,152,471
something is missing
-$880,497
Payments made for
capitalized software
$36,000
Prepaid expenses and
other current assets
$323,604
Change in fair value of
derivative liabilities
$76,264
Change in operating
lease asset and...
-$904
Buy us a coffee
Shuttle Pharmaceuticals Holdings, Inc. (SHPH)
Shuttle Pharmaceuticals Holdings, Inc. (SHPH)